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Abstract
Background: Treatment of enterococcal periprosthetic joint infections (PJI) is challenging due to non-standardized
management strategies and lack of biofilm-active antibiotics. The optimal surgical and antimicrobial therapy are
unknown. Therefore, we evaluated characteristics and outcome of enterococcal PJI.
Methods: Consecutive patients with enterococcal PJI from two specialized orthopedic institutions were retrospectively
analyzed. Both institutions are following the same diagnostic and treatment concepts. The probability of relapse-free
survival was estimated using Kaplan-Meier survival curves and compared by log-rank test. Treatment success was
defined by absence of relapse or persistence of PJI due to enterococci or death related to enterococcal PJI. Clinical
success was defined by the infection-free status, no subsequent surgical intervention for persistent or perioperative
infection after re-implantation and no PJI-related death within 3 months.
Results: Included were 75 enterococcal PJI episodes, involving 41 hip, 30 knee, 2 elbow and 2 shoulder prostheses. PJI
occurred postoperatively in 61 episodes (81%), hematogenously in 13 (17%) and by contiguous spread in one. E.
faecalis grew in 64 episodes, E. faecium in 10 and E. casseliflavus in one episode(s). Additional microorganism(s) were
isolated in 38 patients (51%). Enterococci were susceptible to vancomycin in 73 of 75 isolates (97%), to daptomycin in
all 75 isolates, and to fosfomycin in 21 of 22 isolates (96%). The outcome data was available for 66 patients (88%). The
treatment success after 3 years was 83.7% (95% confidence interval [CI]; 76.1–96.7%) and the clinical success was 67.5%
(95% CI; 57.3–80.8%). In 11 patients (17%), a new PJI episode caused by a different pathogen occurred. All failures
occurred within 3 years after surgery.
Conclusion: About half of enterococcal PJI were polymicrobial infections. The treatment success was high (84%). All
treatment failures occurred within the first 3 years after revision surgery. Interestingly, 17% of patients experienced a
new PJI caused by another pathogen at a later stage.
Trial registration: The study was retrospectively registered with the public clinical trial identification NCT0253022 at
https://www.clinicaltrials.gov on 15 July 2015.
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Background
Enterococci are reported as causing pathogen of
periprosthetic joint infection (PJI) in 2.3 to 15% [1,
2], often as part of a polymicrobial infection [3, 4].
Despite low virulence of the pathogen, the treatment
of enterococcal PJI is challenging due to slow bac-
tericidal activity of antimicrobial agents, antimicro-
bial tolerance and increasing resistance [5]. Data on
biofilm-active antibiotics against enterococci are lim-
ited or not existing, hence enterococcal PJI were
previously classified as “difficult-to-treat” [6]. In
addition, some authors report high treatment failure
rates [7–9].
Management strategies in enterococcal PJI are con-
troversial. Depending on the surgical procedure ap-
plied, divergent outcome results are reported [1, 10–
12]. Similarly, antimicrobial treatment recommenda-
tions vary widely and predominantly originate from
in vitro and experimental studies or are extrapolated
from the guidelines for treatment of infective endo-
carditis. Most authors recommend aminopenicillin de-
rivatives in penicillin-susceptible isolates, whereas
vancomycin and linezolid are suggested for penicillin-
resistant enterococci. Some experts propose single
antimicrobial therapy, while others recommend com-
bination treatment with aminoglycosides or ceftriax-
one [6, 13–15]. Furthermore, the role of rifampin is
controversial [16, 17]. Newer antibiotic options such
as daptomycin, lipoglycopeptides and fosfomycin are
even less investigated for enterococcal PJI [17–19].
We performed a retrospective cohort study in two
orthopedic clinics specialized in endoprothetic septic
surgery, which are following the same diagnostic and
treatment concepts. The aim of the study was to
analyze the clinical, laboratory and microbiological char-
acteristics, treatment modalities and outcome of entero-
coccal PJI.
Methods
Study design and population
This retrospective cohort study was conducted in two
large orthopedic centers, having a specialized septic
surgery unit. PJI episodes caused by Enterococcus spe-
cies, alone or in combination with another microorgan-
ism(s), treated at one of the participating institutions
from January 2010 to December 2017 were included.
Data on PJI were collected using the same definition cri-
teria, diagnostic procedure and outcome evaluation. The
study was approved by the lead ethical committee (ap-
proval No. EA04/040/14) and was conducted in accord-
ance with the Declaration of Helsinki. The study was
registered with the public clinical trial identification
NCT0253022 at https://www.clinicaltrials.gov.
Study definitions
PJI was defined according to the following definition cri-
teria, as previously used [20–22]. According to these cri-
teria, at least one of the following criteria are needed for
the diagnosis of PJI: (i) macroscopic purulence sur-
rounding the prosthesis, (ii) presence of communicating
sinus tract, (iii) increased absolute synovial fluid
leukocyte count or differential (> 2000 leukocytes/μl or >
70% granulocytes), (iv) isolation of enterococci from
synovial fluid, periprosthetic tissue or sonication culture,
(v) positive histopathology, defined as > 23 granulocytes
per 10 high-power fields, corresponding to type II or
type III periprosthetic membrane [23]. If enterococci
grew in only one microbiological specimen, the micro-
biological finding was sufficient for the diagnosis of PJI
only if additional (non-microbiological) criterion was
present, as defined above.
Infections were classified according to their temporal
appearance after surgery into early (< 3months), delayed
(3–24 months) and late infection (> 24months) [24]. In
addition, infections were defined as acute PJI (new onset
symptoms for ≤4 weeks), or chronic PJI (symptoms
duration > 4 weeks). The hematogenous route of PJI was
defined when (i) the onset of the symptoms was > 3
months after implantation and occurred after an initial
uneventful initial course and (ii) the infection presented
with acute onset or the same Enterococcus species grew
in blood cultures or from a distant infectious focus. Each
case was evaluated and classified by an interdisciplinary
team of orthopedic surgeons (DA, RT, CP) and infec-
tious disease specialists (AT, NR).
Infection-free interval describes the interval from pri-
mary implantation or last septic surgery of the prosthesis
to the diagnosis of an enterococcal infection.
Treatment success was defined by absence of relapse
or persistence of PJI due to enterococci or death related
to enterococcal PJI.
Clinical success was defined by the presence of all fol-
lowing criteria at last follow-up: (i) infection-free status,
characterized by a healed wound without fistula, drainage,
and no recurrence of the infection, (ii) no subsequent sur-
gical intervention for persistent or perioperative infection,
and (iii) no PJI-related death (within 3months).
Microbiological testing
An automated broth microdilution assay was used to de-
termine the antimicrobial susceptibility of all antibiotics
except for fosfomycin, and the results were interpreted
according to European Committee on Antimicrobial
Susceptibility Testing (EUCAST) criteria. For fosfomycin,
Etest (bioMérieux, Marcy-l’Étoile, France) was performed
in Müller Hinton agar (BD, Heidelberg, Germany) accord-
ing to manufacturer’s instructions. After incubation at
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Infection manifestation according to the time after last surgery
Early 27 (36) 10 (27) 17 (45) 0.150
Delayed 30 (40) 17 (46) 13 (34) 0.351
Late 18 (24) 10 (27) 8 (21) 0.597
Median delay from last revision to PJI (range) - months 8.7 (0.5–336) 10.2 (0.3–336) 5.0 (0.4–133) 0.588
Median delay from primary implantation of prosthesis to PJI (range) - months 47.7 (0.3–418) 36.4 (0.3–418) 56.6 (0.4–373) 0.810
Presumed route of infection
Perioperativea 61 (81) 25 (68) 36 (95) 0.003
Hematogenous 13 (17) 12 (32) 1 (3) < 0.001
Direct extension by adjacent infectious focus (contiguous) 1 (1) – 1 (3)
Signs and symptoms
Joint pain 48/70 (69) 22/32 (69) 26/38 (68) 1.000
Local signs 46 (61) 20 (54) 26 (68) 0.241
Sinus tract 16 (21) 3 (8) 13 (34) 0.010
Prosthesis loosening in x-ray 16 (21) 5 (14) 11 (29) 0.158
Laboratory results at admission
Serum C-reactive protein
Median (range) - mg/l 36 (1–295) 45 (12–229) 36 (1–295) 0.936
Increased (> 10mg/l) 63 (84) 30 (81) 33 (87) 0.544
White blood cell count
Median (range) – G/l 7.9 (3.2–34.23) 7.4 (4.8–22.4) 8.3 (3.2–34.3) 0.992
Increased (> 10 G/l) 18 (24) 8 (22) 10 (26) 0.788
Synovial fluid leukocyte count
Increased valueb 25/29 (86) 16/17 (94) 9/12 (75) 0.279
Median absolute count (range) - 103/μl 20.3 (0.42–160) 23 (1.8–160) 7.1 (0.4–140) 0.097
Histopathology consistent with infection 53/61 (87) 26/28 (93) 27/33 (82) 0.294
Data are no. (%) of patients, unless otherwise indicated. Where the denominator is shown, data was not available for all patients
aAmong them 13 cases (9 polymicrobial and 4 monomicrobial) occurred during surgical and antimicrobial treatment of a PJI caused by another pathogen
bIncreased absolute number of leukocytes or percentage of granulocytes








Female sex, No. (%) 48 (64) 21 (57) 27 (71) 0.234
Median age (range) - years 76 (30–90) 78 (52–90) 75 (30–89) 0.810
Affected joint, No. (%)
Hip 41 (55) 21 (57) 20 (53) 0.818
Knee 30 (40) 12 (32) 18 (47) 0.241
Elbow 2 (3) 2 (5) – 0.240
Shoulder 2 (3) 2 (5) – 0.240
Previous revision surgery, No. (%) 61 (81) 27 (73) 34 (89) 0.082
Septic revision 34 (56) 16 (59) 18 (53)
Aseptic revision 27 (44) 11 (41) 16 (47)
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37 °C for 24 h, the minimal inhibitory concentration
(MIC) was recorded as the concentration value where the
inhibition ellipse intersected the scale of the strip.
Surgical treatment
All patients underwent revision surgery. Patients with
acute (early postoperative or late hematogenous) infec-
tion with symptoms lasting < 4 weeks were treated with
retention of the prosthesis, change of the mobile parts
and meticulous debridement. In contrast, patients with
chronic PJI, with signs of infection lasting ≥4 weeks or
with a loose prosthesis were treated with one-stage or
two-stage revision, depending on the local soft tissue
and bone conditions and the revision history.
Antimicrobial treatment
Empiric antibiotic treatment was started intravenously
after surgery and was subsequently adapted according to
the susceptibility of the isolated organism. The intraven-
ous treatment was typically continued for at least 2
weeks, followed by oral antibiotic treatment, as previ-
ously described [25, 26]. In case of a two-stage revision,
antibiotics were administered without interruption until
re-implantation. After re-implantation, antibiotics were
continued to complete a total duration of at least 12
weeks (or longer, if the prosthesis-free interval was > 6
weeks).
Adequate antimicrobial therapy was considered when
the antibiotic was appropriate against enterococcal infec-
tion according to its activity, dose, oral bioavailability
and bone penetration. The antibiotics were chosen ac-
cording to institutional treatment guidelines and patient
history of antibiotic allergies. The following intravenous
doses were used in patients with normal renal function:
vancomycin 15–20mg/kg every 12 h, daptomycin 8–10
mg/kg once daily, fosfomycin 5 g every 8 h, penicillin G
5 million IU every 6 h, ampicillin 2 g every 6 h, gentami-
cin 3 mg/kg once daily. In case of concomitant infect-
ive endocarditis, higher doses were administered
according to the respective guidelines.
Follow-up evaluation
Patients were scheduled for follow-up in the outpatient
clinic at 3, 6, 12 and 24months after revision surgery.
Clinical, laboratory and radiological evaluation was per-
formed and interpreted interdisciplinary by an ortho-
pedic surgeon and an infectious disease specialist.
Further follow-up evaluation was performed by phone
contact using a standardized case-report form.









E. faecalis 64 (85) 33 (89) 31 (82) 0.516
E. faeciuma 10 (13) 4 (11) 6 (16) 0.736
E. casseliflavus 1 (1) - 1 (3) 1.000








Source of pathogen isolation
Synovial fluid 42/55 (76) 20/25 (80) 22/30 (73) 0.752
Periprosthetic tissue 52/67 (78) 24/33 (73) 28/34 (82) 0.392
Sonication fluid 33/45 (73) 15/22 (68) 18/23 (78) 0.514
Data are no. (%) of patients, unless otherwise indicated. Where the denominator is shown, data was not available for all patients
aIncluding 2 vancomycin-resistant enterococci (VRE)
bS. epidermidis (n = 14), S. capitis (n = 2), S. lugdunensis (n = 2), S. saccharolyticus (n = 1) and S. haemolyticus (n = 1)
cKlebsiella spp. (n = 6), E. coli (n = 5), Proteus spp. (n = 5), Pseudomonas aeruginosa (n = 4), Morganella spp. (n = 2), Serratia marcescens (n = 1), Enterobacter cloacae
(n = 1), Acinetobacter spp. (n = 1)
dFinegoldia magna (n = 3), Peptinophilus asaccharolyticus (n = 1), Peptostreptococcus micros (n = 1), Bacteroides fragilis (n = 1)
eC. albicans (n = 4), C. parapsilosis (n = 1)
fS. salivarius (n = 1), S. cristatus (n = 1), not further specified (n = 1)
gC. striatum (n = 1), C. tuberculostearicum (n = 1)
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Statistical analysis
Categorical variables were compared using the Fisher’s
exact test, for comparison of continuous variables the
Mann-Whitney U test was applied. A two-sided p-
value of < 0.05 was considered significant. The prob-
ability of infection-free survival and 95% confidence
interval (CI) was estimated using the Kaplan-Meier
survival method. Outcomes between groups were
compared using Fishers exact test. An alpha level of
0.05 was considered significant. For statistical analysis
and graphics, Prism software (version 8.2; GraphPad,
La Jolla, CA, USA) was used.
Results
Patient demographical data
A total of 75 patients were included. The demographics
of 37 monomicrobial and 38 polymicrobial enterococcal
PJI are shown in Table 1. At least one previous revision
surgery was performed in 61 patients (81%), the number
of previous surgeries ranged from 1 to 18 interventions.
Infection characteristics (Table 2)
Twenty-seven episodes (36%) occurred early after sur-
gery, 30 (40%) delayed and 18 (24%) late.
The presumed route of infection was perioperative in
the majority of PJI (81%), whereas the hematogenous
route was documented in 13 episodes (17%). The pri-
mary infection focus was found in 7 cases, including in-
fective endocarditis in four patients and urinary tract
infection in three patients. In 13 patients, enterococci
were detected as second pathogen, isolated during treat-
ment of PJI initially caused by another pathogen.
Enterococcal PJI presented with acute onset in 33 pa-
tients (44%) and with chronic symptoms in 42 (56%).
Sinus tract was more often observed in polymicrobial
than monomicrobial infections (34% vs. 8%, p = 0.010).
Among diagnostic tests, positivity rate of histopathology
of periprosthetic tissue (87%), synovial fluid leukocyte
count (86%) and serum C-reactive protein concentration
(84%) were high, whereas only 18 patients (24%) presented
with elevated serum white blood cell count.
Microbiological findings
Table 3 summarizes the isolated enterococcal species
and source of pathogen isolation. PJI was caused by
E. faecalis in 64 patients (85%), by E. faecium in 10
patients (13%) and by E. casseliflavus in 1 patient
(1%). The most common co-pathogens in polymicro-
bial infections were coagulase-negative staphylococci
and gram-negative bacilli.
Figure 1 summarizes the antimicrobial susceptibil-
ities of enterococci to ampicillin, high-level of genta-
micin and vancomycin. Of 22 enterococcal isolates,
21 had an MIC for fosfomycin of ≤128 mg/l (Fig. 2).
In 13 patients, only one specimen (tissue in 4 patients
and synovial fluid in 9 patients) grew the Enterococcus
spp. In all of them, a non-microbiological criterion was
fulfilled, i.e. among positive histopathology in 9 patients,
purulent secretion in 3 patients and positive synovial
fluid leukocyte count in 1 patient.
Surgical treatment
Table 4 summarizes the surgical and antimicrobial treat-
ment of analyzed patients. Retention of the prosthesis
was performed in 13 patients with acute infection, one-
stage exchange in 10 patients (2 acute and 8 chronic PJI)
Fig. 1 Susceptibility of enterococcus isolates to ampicillin,
gentamicin high-level and vancomycin. HL, high-level
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and two-stage exchange in 43 patients. The median
interval between explantation and re-implantation sur-
gery was 84 days (range, 29–292 days). In 9 patients (4
hips, 4 knees, 1 elbow) resection arthroplasty was
performed.
Antimicrobial treatment
Antimicrobial therapy was administered in 74 patients
(99%), all of them were initially treated with intravenous
antibiotics. Fifty-nine patients (80%) received a combin-
ation therapy with the addition of gentamicin (n = 24),
Fig. 2 Minimal inhibitory concentrations of enterococcal isolates for fosfomycin (n = 22)









Prosthesis retentiona 13 (17) 7 6 0.768
One-stage exchangeb 10 (13) 5 5 1.000
Multi-stage exchangec 43 (57) 20 23 0.644
No. surgical interventions needed, median (range) 2 (2–8) 2 (2–5) 3 (2–8) 0.039
Resection arthroplasty 9 (12) 5 4 0.736
Antimicrobial treatmentd
Intravenous antibiotic agent
Penicillin derivative 61/74 (82) 30/37 (81) 31/37 (84) 1.000
Vancomycin or daptomycin 12/74 (16) 6/37 (16) 6/37 (16) 1.000
Other 1/74 (3) 1/37 (3) –
Additive agent for combination treatment
Fosfomycin 17/74 (23) 9/37 (24) 8/37 (22) 1.000
Gentamicin 16/74 (22) 11/37 (30) 5/37 (14) 0.157
Fosfomycin and gentamicin 8/74 (11) 5/37 (14) 3/37 (8) 0.711
Vancomycin or daptomycin 18/74 (24) 4/37 (11) 14/37 (38) 0.013
None 15/74 (20) 8/37 (22) 7/37 (20) 1.000
Median total duration (range) – weeksd 16 (2–52) 15 (4–39) 16 (2–52) 0.459
Prolonged treatment duration (> 12 weeks) 35/74 (47) 17/37 (46) 18/37 (49) 1.000
Data are no. (%) of patients, unless otherwise indicated. Where the denominator is shown, data was not available for all patients
aIncluding exchange of mobile parts (n = 7), debridement only (n = 4) and no surgery (n = 1)
bIn 3 patients, only partial exchange was performed
cMedian interval between explantation and re-implantation was 84 days (range, 29–292 days)
dOne patient received no antimicrobial treatment
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vancomycin or daptomycin (n = 18) or fosfomycin (n =
25). The median duration of fosfomycin treatment was
14 days (range, 3–90 days).
The antibiotic treatment was considered adequate in
66 patients (88%), which included either penicillin deriva-
tive (in ampicillin-susceptible enterococci) or vancomycin
or daptomycin (in ampicillin-resistant enterococci). The
median duration of antibiotic treatment was 16 weeks
(range, 2–52 weeks).
Outcome evaluation
Table 5 shows outcome data of 66 patients (88%) for
whom the follow-up data was available and who com-
pleted antibiotic therapy. The median follow-up was
31.8 months (range, 0.3–83.3 months). The relapse-free
probability (treatment success) after 3 years was 83.7
(95% CI; 76.1–96.7%) and the infection-free probability
(clinical success) was 67.5% (95% CI; 57.3–80.8%) (Fig. 3).
All failures occurred within 3 years after diagnosis of en-
terococcal PJI. Among 21 patients with clinical failure,
10 experienced persistent infection or relapse due to en-
terococci (treatment failure) and 11 experienced new in-
fection with another microorganism or culture-negative
(nine of which occurred within 12 months). Two pa-
tients died within the first 3 months after surgical revi-
sion related to infection. Of 21 patients with clinical
failure, 18 (86%) had previous revision surgery.
Clinical and treatment outcome according to surgical
procedures is summarized in Fig. 4. Polymicrobial and
monomicrobial infections showed no difference regarding
treatment outcome (88% vs. 82%, p = 0.733). Adequate
antimicrobial treatment was associated with better treat-
ment outcome compared to inadequate therapy (91% vs.
38%, p = 0.002). No statistical difference was observed in
the treatment outcome in patients receiving antimicrobial
monotherapy or combination therapy (88% vs. 73%, p =
0.217), neither in those receiving fosfomycin in their treat-
ment regimen (95%) compared to those without fosfomy-
cin (80%) (p = 0.261). Prolonged antimicrobial therapy of
> 12 weeks was also not associated with better treatment
outcome than shorter therapy (81% vs. 85%, respectively,
p = 0.920).
Discussion
Outcome reports of enterococcal PJI vary widely, to a
certain extent due to heterogeneous definition of treat-
ment success. While some authors defined failure as re-
lapse or persistent infection with isolation of the same
pathogen, others also considered new infections caused
by other pathogens as failures. In our study, failures
were subclassified as treatment or clinical failure and
success, respectively. Considering these definitions, the
eradication of enterococcal PJI (treatment success) in
our cohort was 83.7%, which was higher than previously
reported (50 to 76%) [1, 9, 12, 27]. However, as 11 pa-
tients experienced new infection with another micro-
organism or were culture-negative, the infection-free
probability (clinical success) was only 67.5%.
Rasouli et al. [1] described clinical success in 32 of 36
patients (89%) and treatment success in 35 of 36 patients
(97%) with enterococcal PJI. However, in several patients
additional major surgeries were performed such as re-
section arthroplasty, two-stage exchange, above-knee
amputation or fusion. The fact that in our study no new
PJIs occurred in patients with prosthesis retention and
only in one patient undergoing one-stage exchange, cor-
roborates the assumption that multiple surgeries may be
a risk factor for introduction of a new pathogen. It re-
mains unclear whether these infections are really “new”
or a relapse of an unrecognized initial pathogen.
Whereas adequate antimicrobial treatment was associ-
ated with better treatment outcome, prolonged anti-
microbial therapy of > 12 weeks did not influence the
outcome.
The EUCAST recommendations do not provide break-
points for enterococci and fosfomycin and, thus, this
substance is not recommended as monotherapy for the
treatment of enterococcal infections. However, in vitro








Median follow-up (range) – months 31.8 (0.3–83.8) 25.9 (1.4–78.6) 33.8 (0.3–83.8) 0.138
Clinical success 45 (68) 22 (66) 23 (70) 1.000
Clinical failurea 21 (31) 11 (33) 10 (30)
Isolation of another or no pathogen 11 5 6
Treatment failureb 10 6 4
Treatment success 56 (85) 27 (82) 29 (88) 0.752
Data are no. (%) of patients, unless otherwise indicated. Where the denominator is shown, data was not available for all patients
a6 patients died, 2 death were associated with the enterococcal PJI (treatment failure), 1 death was related to a new infection caused by staphylococci in the later
course (clinical failure) and 3 patients died from a non-infectious cause (1 tumor, 2 pulmonary embolism) and were considered infection-free at the time of death
bPersistent infection or relapse with same Enterococcus spp. as initially isolated
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and animal model data showed activity of fosfomycin
against planktonic and adherent E. faecalis. The most ef-
ficient regimen for killing planktonic and adherent E.
faecalis was the combination of fosfomycin and gentami-
cin [17]. Extrapolated from the recommendation for the
use of fosfomycin as combination partner for the treat-
ment of infections caused by wild type isolates of
Pseudomonas spp. with an epidemiological cut-off of
128 mg/l [28], the same cut-off is also used for entero-
cocci and intravenous fosfomycin in daily routine. In our
cohort, fosfomycin was active against most enterococcal
isolates using the aforementioned fosfomycin MIC cut-
off value. When intravenous fosfomycin (5 g every 8 h
intravenously) was included in the treatment regimen,
the treatment outcome was numerically higher than
without intravenous fosfomycin (95% vs. 80%), however,
the difference did not reach statistical significance. Pro-
spective randomized controlled trials are needed to fur-
ther explore the role of fosfomycin in biofilm-related
infections.
Debridement and prosthesis retention was associated
with the highest treatment success; however, this
Fig. 3 Outcome analysis of 75 patient with enterococcal PJI. Treatment failure (a) and clinical failure (b). Dotted lines indicate the 95%
confidence interval
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observation is most likely biased by rather treating “un-
complicated” and acute infections with retention and
more complex ones with prosthesis removal. This fact
represents the main limitation of the study. Other stud-
ies reported low clinical success with debridement and
retention such as 40% [9], 47% [27], 50% [1] and 66%
[11] and based on this observation two-stage prosthesis
exchange is recommended for enterococcal PJI. How-
ever, with improved antimicrobial therapy, debridement
and retention or one-stage prosthesis exchange may be-
come an alternative to two-stage exchange with high
treatment success. Based on our data, in our institu-
tion PJI caused by enterococci are no longer managed as
difficult-to-treat infections as previously suggested [6].
Of note, permanent removal of prosthesis (resection
arthroplasty without reimplantation) was performed in
in 9 patients (12%) in our cohort. These patients were
cured from infection, although the result may represent
a functional inferior outcome, if they were able to walk
before occurrence of PJI. Reasons for choosing resection
arthroplasty were high risk of complications due to add-
itional surgery, exceptionally insufficient bone stock or
bedriddeness of patients.
In a previous study, the clinical presentation of entero-
coccal PJI was similar to that caused by low-virulent or-
ganisms such as Cutibacterium acnes and coagulase-
negative staphylococci [12]. Accordingly, it remains un-
clear whether enterococci are true pathogens or contam-
inants when grown in a single specimen. If isolated in a
single specimen, typical members of the normal skin
flora are considered contaminants. As enterococci are not
typically colonizing the skin, contamination during sam-
pling appears unlikely. A similar question was investigated
by Jindai et al. for positive blood cultures for enterococci
[29]. The authors concluded that single-positive blood cul-
tures likely indicate true infection rather than contamin-
ation, as the clinical outcome of patients with single-
positive blood cultures was similar to those with multiple-
positive blood cultures. In our study at least two positive
Enterococcus spp. cultures were required, as defined
by other authors evaluating enterococcal PJI [1, 9,
12]. However, a single positive culture was accepted if
an additional non-microbiological criterion was
present.
All treatment failures in our cohort occurred within
the first 3 years after treatment of enterococcal PJI.
Based on this finding, we recommend close follow-up in
the first years, whereas the likelihood of relapse after-
wards seems low. The risk of hematogenous PJI, how-
ever, remains during the whole indwelling time of the
prosthesis, as recently demonstrated [30].
Conclusions
Although the retrospective design of the study and the
limited number of patients make definitive conclusions
regarding outcome difficult, some important finding can
be deduced from the presented study. First, about half of
enterococcal PJI were polymicrobial infections. Second,
the treatment success was unexpectedly high (84%), sug-
gesting that enterococcal PJI are not difficult to treat. All
treatment failures occurred within the first 3 years after
revision surgery. Third, 17% of patients experienced a
new PJI caused by another pathogen at a later stage.
Fourth, intravenous fosfomycin was active against 21 of
22 enterococcal isolates (MIC ≤128 μg/ml) and its
value should be further explored in prospective clinical
trials involving enterococcal PJI.
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